Skip to main content

New story in Health from Time: A First-of-its-Kind Library of Potential Coronavirus Drugs, Built at Columbia University, Funded by China’s Richest Person



If our experience with coronaviruses in the past few decades has taught us anything, it’s that outbreaks are inevitable, no matter what we do. You don’t have to look further than the fact that COVID-19 is the third coronavirus epidemic to affect human populations in 20 years, after severe acute respiratory syndromes (SARS) in 2003 and Middle East respiratory syndrome (MERS) in 2012. Coronaviruses make their homes in a variety of animal hosts, from bats to cats, dogs to camels, and it’s just a matter of time before another one makes the jump into people.

Another thing we know for sure is that we can’t rely on patchwork responses each time an outbreak occurs. Every time a new coronavirus emerges, researchers focus their attention on learning everything they can about the culprit, and biotech companies dip a careful toe into the investigational waters of developing a new treatment, but ultimately, when the cases subside, so does the interest and so does the research.

Dr. David Ho, CEO of the Aaron Diamond AIDS Research Center and professor of medicine at Columbia University, wants to put an end to that trend. Ho is a leader in the HIV field, having done groundbreaking research on how the virus works in the body, and pioneering the idea of combating infection early and with the strongest possible arsenal of combined anti-virals. Now, he’s turning to coronaviruses, hoping his HIV expertise will help him figure out how best to treat and contain novel coronaviruses. With a $2.1 million starting grant from Chinese technology mogul Jack Ma, Ho will oversee four research teams at Columbia whose goal is to find an effective treatment against COVID-19 and other coronaviruses.

“We put together a proposal in record time—probably no more than 72 hours,” says Ho. “We predict in the coming decade there will be more [outbreaks]. And we need to find permanent solutions. We should not repeat the mistake we made after SARS and after MERS, that once the epidemic wanes, the interest and the political will and the funding also wanes. If we had followed through with the work that had begun with SARS, we would be so much better off today.”

To ensure that the next response to a coronavirus outbreak is better than this one, Ho and his team are building a first-of-its-kind library of potential coronavirus drug candidates. Coronavirus, like HIV, is a retrovirus, meaning its primary genetic material is made up of RNA, which the virus then translates into DNA when it infects a host cell. So Ho is stacking his shelves with polymerase and protease inhibitors, and other drugs that have been developed to fight HIV and other viruses like viral hepatitis. Ho says there are about 4,700 of these drugs, if you include their analogues (drugs that are structurally similar but may be made using slightly different formulas and might have varying side effect profiles). Because viruses seem to share some basic processes to replicate, that means there’s a strong chance of finding something that might be effective against not just SARS-CoV-2 but other coronaviruses that might pop up in coming years.

Ho is also studying samples from people infected with COVID-19 to find antibodies that might be attacking the virus—applying a strategy his team has been using to find new approaches to treating HIV.

Other researchers are tracking strains of coronavirus currently living in animals like bats, so together with the library of potential drug candidates, Ho says it might be possible to better combat the next coronavirus infection. “We have a goal to have [some] lead candidates [to treat COVID-19] in one year’s time. So we really have to get going,” says Ho. “But if we had done something like this after SARS and MERS, we would be further along already.”

Labels:

Popular posts from this blog

New story in Health from Time: Here’s How Quickly Coronavirus Is Spreading in Your State

The novel coronavirus pandemic is a global crisis, a national emergency and a local nightmare. But while a great deal of the focus in the U.S. has been on the federal government’s response, widely criticized as slow and halting , the picture on the ground remains very different in different parts of the country. A TIME analysis of the per capita spread of the epidemic in all 50 states and Washington, D.C. found considerable range in the rate of contagion, and, in some parts of the country, a significant disparity compared to the national figure. The U.S., unlike nations such as South Korea and now Italy , has yet to show signs of bringing the runaway spread of the virus under control. However, while no single state is yet showing strong signs of bending the curve , some are faring much worse than others. The following graphic plots the rise in the total confirmed cases of COVID-19 per 100,000 residents in each state, plotted by the day that each state reported its first case.
Read more

New story in Health from Time: We Need to Take Care of the Growing Number of Long-term COVID-19 Patients

On July 7, 2020, the Boston Red Sox pitcher Eduardo Rodriguez tested positive for the new coronavirus. He was scheduled to start Opening Day for the Sox, but the virus had other plans— damaging Rodriguez’s heart and causing a condition called myocarditis (inflammation of the heart muscle). Now the previously fit 27-year old ace left-hander must sit out the 2020 season to recover. Rodriguez is not alone in having heart damage from SARS-CoV-2, the virus that causes COVID-19. In a new study done in Germany, researchers studied the hearts of 100 patients who had recently recovered from COVID-19. The findings were alarming: 78 patients had heart abnormalities, as shown by a special kind of imaging test that shows the heart’s structure (a cardiac MRI), and 60 had myocarditis. These patients were mostly young and previously healthy . Several had just returned from ski trips. While other studies have shown a lower rate of heart problems—for example, a study of 416 patients hosp
Read more

New story in Health from Time: What We Don’t Know About COVID-19 Can Hurt Us

Countries around the world have introduced stringent control measures to stop COVID-19 outbreaks growing, but now many find themselves facing the same situation again. From Melbourne to Miami, the relaxation of measures had led to increasing flare-ups, which in some places has already meant reclosing schools, businesses or travel routes. Within the U.S. and among different countries , places with wildly varying public-health policies have experienced wildly diverse outcomes. Most ominously, infections are rising rapidly in many places where they once were falling. So how do countries avoid an indefinite, unsustainable, cycle of opening and closing society? What is needed to prevent a future of strict social distancing and closed borders? To escape this limbo, we need to know more about each step in the chain of infection: why some people are more susceptible or have more symptoms, how our interactions and surroundings influence risk, and how we can curb the impact of the re
Read more